Loading
Breast Cancer Treatment Studies / Advanced Breast Cancer Therapies · Journal article
Molecules · July 22, 2026
A consensus or society position rather than new primary data.
This is a comprehensive narrative review that summarizes current understanding of breast cancer epidemiology, molecular classification, diagnostic methods, and established and emerging therapeutic strategies. It presents descriptive overviews of treatment paradigms and future directions but does not provide new efficacy data, comparative outcomes, or quantitative evidence to inform clinical decision-making.
Narrative review. Women with breast cancer, including localized, advanced, and metastatic disease; emphasis on triple-negative breast cancer as an aggressive subtype..
Breast cancer diagnosis involves clinical examination, imaging (mammography, ultrasound), and confirmatory biopsies. Localized disease treatment includes surgery (lumpectomy or mastectomy), radiotherapy, and systemic therapies tailored to tumor biology including endocrine therapy, HER2-targeted therapy, and CDK4/6 inhibitors. Advanced or metastatic breast cancer therapies include immunotherapy, PARP inhibitors for BRCA-mutated cancers, antibody-drug conjugates, and novel targeted agents.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review serves as a reference for the current clinical landscape of breast cancer management and emerging research directions. It does not provide outcome data or comparative efficacy to guide specific treatment decisions, but contextualizes molecular profiling and personalized approaches as evolving standards.
This is a narrative review synthesizing current knowledge on breast cancer epidemiology, diagnostics, and treatment paradigms, presenting established and emerging clinical approaches without original data or new evidence.
As stated by the source record.
This review serves as a reference for the current clinical landscape of breast cancer management and emerging research directions. It does not provide outcome data or comparative efficacy to guide specific treatment decisions, but contextualizes molecular profiling and personalized approaches as evolving standards.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Breast cancer remains one of the most prevalent malignancies affecting women worldwide and continues to be a leading cause of cancer-related morbidity and mortality. Patients may present with either localized or advanced disease, with clinical outcomes increasingly influenced by molecular subtype and genetic profile. This review highlights the key genetic factors involved in breast cancer, current diagnostic and therapeutic strategies, and promising emerging approaches that may shape future clinical management. Breast cancer diagnosis typically involves clinical breast examination, imaging techniques such as mammography and ultrasound, and confirmatory biopsies. Genetic mutations in specific genes are strongly linked to the development, progression, and metastasis of the disease. Treatment options for localized breast cancer continue to include surgery (lumpectomy or mastectomy) and radiotherapy, combined with systemic therapies tailored to tumor biology, such as endocrine therapy, human epidermal growth factor receptor 2 (HER2)-targeted therapy, and cyclin-dependent kinase (CDK)4/6 inhibitors. For advanced or metastatic breast cancer, recent therapeutic advances include the use of immunotherapy (e.g., immune checkpoint inhibitors), Poly (ADP-ribose) polymerase (PARP) inhibitors for Breast Cancer gene (BRCA)-mutated cancers, antibody-drug conjugates, and novel targeted agents, which have significantly improved patient outcomes in selected populations. Recent findings in breast cancer genetics have highlighted the critical role of germline and somatic mutations, particularly in genes such as BRCA1, BRCA2, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), and TP53, in driving tumor initiation, progression, and therapeutic response. Molecular profiling and next-generation sequencing technologies have enabled more precise tumor classification and facilitated the development of personalized treatment strategies. Despite these advances, treatment resistance and disease recurrence remain major challenges, particularly in aggressive subtypes such as triple-negative breast cancer. Consequently, ongoing research is exploring alternative and complementary approaches, including nanotechnology-based drug delivery systems, gene editing techniques such as clustered regularly interspaced short palindromic repeats-Cas9 (CRISPR-associated protein 9) (CRISPR-Cas9), cancer vaccines, and the integration of traditional and plant-derived compounds. These strategies aim to enhance therapeutic efficacy, reduce systemic toxicity, and overcome resistance mechanisms.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.